Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,898,551
  • Shares Outstanding, K 82,300
  • Annual Sales, $ 434,250 K
  • Annual Income, $ -606,640 K
  • 60-Month Beta 0.66
  • Price/Sales 8.84
  • Price/Cash Flow N/A
  • Price/Book 13.91
Trade RARE with:

Options Overview Details

View History
  • Implied Volatility 92.02% ( -0.48%)
  • Historical Volatility 46.21%
  • IV Percentile 95%
  • IV Rank 91.23%
  • IV High 97.52% on 10/05/23
  • IV Low 34.83% on 12/22/23
  • Put/Call Vol Ratio 2.27
  • Today's Volume 144
  • Volume Avg (30-Day) 320
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 9,756
  • Open Int (30-Day) 8,469

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.72
  • Number of Estimates 11
  • High Estimate -1.40
  • Low Estimate -2.02
  • Prior Year -2.33
  • Growth Rate Est. (year over year) +26.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.22 +0.80%
on 03/15/24
54.56 -14.61%
on 03/01/24
-2.33 (-4.76%)
since 02/16/24
3-Month
41.87 +11.27%
on 01/18/24
54.56 -14.61%
on 03/01/24
+0.93 (+2.04%)
since 12/18/23
52-Week
31.52 +47.81%
on 10/24/23
54.98 -15.26%
on 06/06/23
+8.06 (+20.92%)
since 03/17/23

Most Recent Stories

More News
Ultragenyx: Q4 Earnings Snapshot

Ultragenyx: Q4 Earnings Snapshot

RARE : 46.59 (-1.65%)
Ultragenyx: Q3 Earnings Snapshot

Ultragenyx: Q3 Earnings Snapshot

RARE : 46.59 (-1.65%)
Ultragenyx: Q2 Earnings Snapshot

Ultragenyx: Q2 Earnings Snapshot

RARE : 46.59 (-1.65%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 20.09 (-0.20%)
RARE : 46.59 (-1.65%)
SRPT : 123.97 (+0.75%)
PFE : 27.72 (-0.79%)
EXEL : 23.17 (+0.83%)
MRNA : 104.26 (+0.39%)
UTHR : 233.97 (-0.77%)
BIIB : 219.40 (+0.04%)
SNY : 47.83 (-0.95%)
LLY : 762.66 (+1.13%)
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

REGN : 959.92 (-0.47%)
RARE : 46.59 (-1.65%)
APTX : 0.0960 (+3.11%)
ETNB : 12.60 (-6.80%)
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RARE : 46.59 (-1.65%)
THMO : 0.7300 (-3.82%)
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 46.59 (-1.65%)
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALLO : 4.20 (-9.98%)
RARE : 46.59 (-1.65%)
Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 10.71 (-0.93%)
RARE : 46.59 (-1.65%)
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

RARE : 46.59 (-1.65%)
GMAB : 29.69 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 48.92
2nd Resistance Point 48.43
1st Resistance Point 47.51
Last Price 46.59
1st Support Level 46.10
2nd Support Level 45.61
3rd Support Level 44.69

See More

52-Week High 54.98
Last Price 46.59
Fibonacci 61.8% 46.02
Fibonacci 50% 43.25
Fibonacci 38.2% 40.48
52-Week Low 31.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar